COLL - Collegium Pharmaceutical Inc Stock Price, Fair Value and News

32.47-1.20 (-3.56%)Market Closed

Market Summary

32.47-1.20

Market Closed

-3.56%

COLL Alerts

Big jump in Earnings (Y/Y)

COLL Stock Price

View Fullscreen

COLL RSI Chart

COLL Valuation

Market Cap

1.1B

Price/Earnings (Trailing)

11.39

Price/Sales (Trailing)

1.87

EV/EBITDA

3.91

Price/Free Cashflow

3.45

COLL Price/Sales (Trailing)

COLL Profitability

EBT Margin

22.92%

Return on Equity

41.99%

Return on Assets

8.37%

Free Cashflow Yield

29.01%

COLL Fundamentals

COLL Revenue

Revenue (TTM)

566.9M

Rev. Growth (Yr)

0.11%

Rev. Growth (Qtr)

-3.22%

COLL Earnings

Earnings (TTM)

93.3M

Earnings Growth (Yr)

259.03%

Earnings Growth (Qtr)

-13.23%

Breaking Down COLL Revenue

Last 7 days

3.1%

Last 30 days

-8.4%

Last 90 days

-0.3%

Trailing 12 Months

44.1%

How does COLL drawdown profile look like?

COLL Financial Health

Current Ratio

1.21

COLL Investor Care

Buy Backs (1Y)

5.43%

Diluted EPS (TTM)

2.4

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	566.9M	0	0	0
2023	524.9M	536.9M	546.6M	566.8M
2022	272.9M	313.5M	361.7M	463.9M
2021	321.2M	326.1M	325.8M	276.9M
2020	298.7M	301.7M	307.9M	310.0M
2019	291.2M	293.2M	295.9M	296.7M
2018	90.1M	159.6M	217.8M	280.4M
2017	7.5M	13.2M	19.0M	28.5M
2016	6.8M	5.1M	3.4M	1.7M
2015	0	0	10.2M	8.5M
2013	0	0	0	12.0M

Get all data in R, Python etc through our Historical Stock Data APIs

GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224

Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index

Very Expensive Stocks

Very Cheap Stocks

Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Collegium Pharmaceutical Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Feb 29, 2024	smith thomas b	sold	-36,580	36.764	-995	evp and chief medical officer
Feb 26, 2024	dreyer scott	sold	-364,270	36.427	-10,000	evp & chief commercial officer
Feb 12, 2024	tupper colleen	acquired	-	-	71,456	evp & chief financial officer
Feb 12, 2024	ciaffoni joseph	acquired	-	-	298,734	president and ceo
Feb 12, 2024	dreyer scott	acquired	-	-	67,286	evp & chief commercial officer
Feb 12, 2024	smith thomas b	sold (taxes)	-107,806	33.7	-3,199	evp and chief medical officer
Feb 12, 2024	dreyer scott	sold (taxes)	-1,000,550	33.7	-29,690	evp & chief commercial officer
Feb 12, 2024	smith thomas b	acquired	-	-	35,423	evp and chief medical officer
Feb 12, 2024	kuhlmann shirley r.	sold (taxes)	-1,070,180	33.7	-31,756	evp and general counsel
Feb 12, 2024	tupper colleen	sold (taxes)	-887,018	33.7	-26,321	evp & chief financial officer

Which funds bought or sold COLL recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 16, 2024	COMERICA BANK	added	62.5	498,591	973,673	-%
May 16, 2024	JANE STREET GROUP, LLC	added	150	834,483	1,219,880	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-11.19	135,761	1,266,460	-%
May 15, 2024	Point72 Asia (Singapore) Pte. Ltd.	added	544	267,814	305,411	0.08%
May 15, 2024	Teza Capital Management LLC	new	-	365,801	365,801	0.05%
May 15, 2024	Centiva Capital, LP	added	65.99	232,529	445,188	0.01%
May 15, 2024	IHT Wealth Management, LLC	new	-	248,448	248,448	0.01%
May 15, 2024	AMERIPRISE FINANCIAL INC	reduced	-3.61	672,894	3,792,170	-%
May 15, 2024	Squarepoint Ops LLC	reduced	-3.28	262,058	1,454,350	-%
May 15, 2024	QUADRANT CAPITAL GROUP LLC	unchanged	-	1,142	5,513	-%

Are Funds Buying or Selling COLL?

Are funds buying COLL calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own COLL

No. of Funds

COLL Alerts

Big jump in Earnings (Y/Y)

Unveiling Collegium Pharmaceutical Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	eventide asset management, llc	8.07%	2,630,478	SC 13G/A
Feb 13, 2024	vanguard group inc	7.09%	2,312,786	SC 13G/A
Feb 12, 2024	rubric capital management lp	8.46%	2,758,253	SC 13G/A
Jan 19, 2024	blackrock inc.	17.7%	5,786,527	SC 13G/A
Feb 10, 2023	rubric capital management lp	9.93%	3,333,628	SC 13G/A
Feb 09, 2023	janus henderson group plc	4.4%	1,481,170	SC 13G/A
Feb 09, 2023	vanguard group inc	6.58%	2,208,111	SC 13G/A
Jan 30, 2023	blackrock inc.	17.1%	5,731,305	SC 13G/A
Sep 09, 2022	janus henderson group plc	5.8%	1,987,495	SC 13G/A
Feb 15, 2022	perceptive advisors llc	0%	0	SC 13G/A

Recent SEC filings of Collegium Pharmaceutical Inc

View All Filings

Date Filed	Form Type	Document
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 16, 2024	4	Insider Trading
May 14, 2024	144	Notice of Insider Sale Intent
May 13, 2024	8-K	Current Report

Peers (Alternatives to Collegium Pharmaceutical Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
JNJ	372.2B	85.6B	6.82%	-1.69%	9.67	4.35	5.68%	202.39%
MRK	332.3B	61.4B	4.65%	15.09%	144.1	5.41	6.11%	-82.30%
AMGN	167.7B	29.5B	18.35%	39.38%	44.55	5.68	12.76%	-52.47%
PFE	162.3B	57.8B	12.71%	-21.46%	129.52	2.81	76.51%	-86.81%
GILD	84.4B	27.4B	1.23%	-13.37%	174.21	3.07	1.51%	-91.32%
TEVA	18.4B	16.0B	23.52%	97.09%	-37.29	1.15	7.23%	71.10%
MID-CAP
ALKS	4.1B	1.7B	0.67%	-19.91%	9.41	2.37	54.01%	364.56%
PRGO	4.1B	4.6B	-0.70%	-10.77%	-528.11	0.89	-0.06%	94.55%
BHC	2.5B	9.0B	-21.94%	-21.03%	-5.45	0.28	10.01%	-27.45%
AMPH	2.1B	676.2M	8.56%	-0.82%	13.75	3.14	30.38%	66.04%
SMALL-CAP
TLRY	1.5B	743.2M	15.12%	-18.85%	-4.35	2.06	24.65%	80.36%
TXMD	25.8M	1.3M	18.52%	-47.17%	-3.49	19.84	-98.14%	-104.71%
ACRX	18.4M	89.6M	6.93%	25.60%	-1.29	0.19	287.27%	-129.41%
AGRX	2.5M	21.5M	2.70%	-90.89%	-0.32	0.12	66.16%	61.83%
ACOR	633.5K	115.7M	-50.00%	-97.38%	0	0.01	-2.22%	-352.48%

Collegium Pharmaceutical Inc News

Latest updates

Collegium Pharmaceutical Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-3.2%	145	150	137	136	145	130	127	124	84.00	27.00	79.00	83.00	88.00	76.00	79.00	78.00	77.00	74.00	73.00	75.00	75.00
Gross Profit	-3.4%	91.00	95.00	80.00	74.00	77.00	50.00	59.00	52.00	48.00	-1.33	46.00	50.00	56.00	44.00	48.00	48.00	39.00	25.00	26.00	26.00	25.00
Costs and Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	77.00	79.00	80.00	85.00
Operating Expenses	27.4%	42.00	33.00	35.00	38.00	53.00	38.00	38.00	41.00	59.00	33.00	32.00	34.00	34.00	29.00	29.00	32.00	34.00	27.00	33.00	31.00	35.00
S&GA Expenses	27.4%	42.00	33.00	35.00	38.00	53.00	38.00	38.00	41.00	55.00	27.00	31.00	30.00	31.00	27.00	26.00	29.00	31.00	25.00	30.00	29.00	32.00
R&D Expenses	-	-	-	-	-	-	-	-	-	4.00	2.00	1.00	3.00	3.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	3.00
EBITDA Margin	30.9%	0.38*	0.29*	0.20*	0.15*	0.10*	0.08*	-0.03*	-0.05*	-0.04*	0.07*	0.21*	0.23*	-	-	-	-	-	-	-	-	-
Interest Expenses	-9.4%	17.00	19.00	21.00	22.00	21.00	21.00	19.00	18.00	6.00	5.00	5.00	5.00	6.00	8.00	8.00	8.00	5.00	0.00	0.00	0.00	0.00
Income Taxes	-39.7%	9.00	15.00	8.00	5.00	-0.13	-0.59	1.00	-1.45	-2.77	-13.84	1.00	-61.85	-0.19	0.00	0.00	0.00	0.00	-	-	-	-
Earnings Before Taxes	-21.6%	37.00	47.00	29.00	18.00	-17.56	-7.79	1.00	-6.65	-15.84	-38.88	9.00	11.00	15.00	7.00	12.00	8.00	0.00	-2.20	-6.11	-4.71	-
EBT Margin	71.5%	0.23*	0.13*	0.04*	-0.01*	-0.06*	-0.06*	-0.17*	-0.17*	-0.13*	-0.01*	0.13*	0.14*	-	-	-	-	-	-	-	-	-
Net Income	-13.2%	28.00	32.00	21.00	13.00	-17.43	-7.20	0.00	-5.19	-13.07	-25.03	8.00	73.00	16.00	7.00	11.00	8.00	0.00	-2.20	-6.11	-4.71	-9.70
Net Income Margin	93.7%	0.16*	0.08*	0.02*	-0.02*	-0.06*	-0.05*	-0.12*	-0.11*	0.16*	0.26*	0.32*	0.33*	-	-	-	-	-	-	-	-	-
Free Cashflow	-16.1%	61.00	73.00	74.00	100	27.00	65.00	43.00	40.00	-25.42	36.00	17.00	29.00	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-2.5%	1,114	1,143	1,178	1,214	1,214	1,174	1,201	1,246	1,246	692	742	714	646	644	644	647	635	306	304	302	294
Current Assets	0.3%	539	538	537	537	498	420	405	410	364	316	363	319	296	278	262	251	224	256	250	245	234
Cash Equivalents	-3.9%	230	239	259	284	269	174	134	123	107	186	193	203	183	177	165	146	116	170	154	149	135
Inventory	-3.3%	31.00	32.00	34.00	26.00	33.00	47.00	65.00	78.00	80.00	17.00	17.00	20.00	15.00	16.00	17.00	19.00	16.00	10.00	9.00	10.00	9.00
Net PPE	-3.3%	15.00	16.00	17.00	18.00	19.00	20.00	20.00	20.00	20.00	19.00	20.00	20.00	20.00	19.00	18.00	15.00	13.00	12.00	12.00	10.00	10.00
Goodwill	0%	134	134	134	134	134	134	130	130	134	-	-	-	-	-	-	-	-	-	-	-	-
Liabilities	-5.9%	892	948	999	1,013	1,035	979	1,004	1,048	1,050	489	491	461	476	458	471	491	494	219	220	216	208
Current Liabilities	-2.5%	446	458	465	435	413	434	414	415	374	280	269	227	230	239	242	252	244	202	201	196	189
Shareholder's Equity	13.7%	222	195	179	201	180	195	197	198	196	203	251	253	170	186	173	156	141	87.00	84.00	86.00	86.00
Retained Earnings	11.9%	-205	-233	-265	-285	-298	-281	-274	-274	-269	-256	-231	-239	-312	-333	-340	-351	-359	-359	-357	-351	-346
Additional Paid-In Capital	-0.1%	565	566	546	548	540	538	526	520	513	502	500	492	482	519	513	507	500	447	442	437	433
Shares Outstanding	2.6%	33.00	32.00	34.00	35.00	34.00	34.00	34.00	34.00	34.00	35.00	35.00	35.00	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	742	-	-	-	600	-	-	-	831	-	-	-	599	-	-	-	416	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-15.5%	61,937	73,338	74,018	99,722	27,671	66,325	42,769	40,451	-25,315	36,198	17,254	29,535	20,570	22,577	34,180	43,854	-6,669	15,656	6,069	14,627	-8,569
Share Based Compensation	6.8%	7,475	7,002	7,027	7,072	6,035	5,670	5,377	5,692	6,135	4,912	5,948	6,516	6,879	6,210	5,165	5,584	4,951	3,966	4,137	4,162	4,263
Cashflow From Investing	27.8%	-18,128	-25,097	-3,822	-41,717	-176	-940	-113	-461	-572,177	-515	-276	-725	-428	-1,481	-2,403	-2,241	-367,647	-889	-1,351	-875	-3,323
Cashflow From Financing	20.2%	-54,146	-67,826	-95,413	-45,236	68,297	-25,823	-31,252	-23,966	517,764	-42,498	-26,508	-8,829	-11,468	-12,403	-12,032	-12,211	323,120	1,414	407	51.00	169
Buy Backs	-100.0%	-	25,000	-	-	-	7,641	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

COLL Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues
Total product revenues, net	$ 144,923	$ 144,767
Revenue from Contract with Customer, Product and Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Cost of product revenues
Cost of product revenues (excluding intangible asset amortization)	$ 18,950	$ 29,899
Cost, Product and Service [Extensible List]	us-gaap:ProductMember	us-gaap:ProductMember
Intangible asset amortization	$ 34,517	$ 37,466
Total cost of product revenues	53,467	67,365
Gross profit	91,456	77,402
Operating expenses
Selling, general and administrative	41,982	52,775
Total operating expenses	41,982	52,775
Income from operations	49,474	24,627
Interest expense	(17,339)	(21,427)
Interest income	4,487	2,747
Loss on extinguishment of debt		(23,504)
Income (loss) before income taxes	36,622	(17,557)
Provision for (benefit from) income taxes	8,909	(131)
Net income (loss)	$ 27,713	$ (17,426)
Earnings (loss) per share - basic (in $ per share)	$ 0.86	$ (0.51)
Weighted-average shares - basic	32,326,589	34,319,291
Earnings (loss) per share - diluted (in $ per share)	$ 0.71	$ (0.51)
Weighted-average shares - diluted	41,438,466	34,319,291

COLL Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets
Cash and cash equivalents	$ 228,610	$ 238,947
Marketable securities	89,438	71,601
Accounts receivable, net	174,693	179,525
Inventory	31,276	32,332
Prepaid expenses and other current assets	15,243	15,195
Total current assets	539,260	537,600
Property and equipment, net	15,457	15,983
Operating lease assets	5,813	6,029
Intangible assets, net	387,191	421,708
Restricted cash	1,047	1,047
Deferred tax assets	30,671	26,259
Other noncurrent assets	954	825
Goodwill	133,857	133,857
Total assets	1,114,250	1,143,308
Current liabilities
Accounts payable	6,020	8,692
Accrued liabilities	38,190	37,571
Accrued rebates, returns and discounts	217,880	227,331
Current portion of term notes payable	183,333	183,333
Current portion of operating lease liabilities	1,013	988
Total current liabilities	446,436	457,915
Term notes payable, net of current portion	177,360	221,713
Convertible senior notes	262,425	262,125
Operating lease liabilities, net of current portion	5,860	6,124
Total liabilities	892,081	947,877
Commitments and contingencies (refer to Note 14)
Shareholders' equity:
Preferred stock, $0.001 par value; authorized shares - 5,000,000
Common stock, $0.001 par value; authorized shares - 100,000,000; 39,029,639 issued and 32,705,747 outstanding shares as of March 31, 2024 and 38,192,441 issued and 31,868,549 outstanding shares as of December 31, 2023	39	38
Additional paid-in capital	565,111	565,949
Treasury stock, at cost; 6,323,892 shares as of March 31, 2024 and 6,323,892 shares as of December 31, 2023	(137,381)	(137,381)
Accumulated other comprehensive (loss) income	(124)	14
Accumulated deficit	(205,476)	(233,189)
Total shareholders' equity	222,169	195,431
Total liabilities and shareholders' equity	$ 1,114,250	$ 1,143,308

About Collegium Pharmaceutical Inc

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003. Collegium Pharmaceutical, Inc. was incorporated in 2002 and is headquartered in Stoughton, Massachusetts.

CEO	Mr. Joseph J. Ciaffoni
WEBSITE	collegiumpharma.com
INDUSTRY	Pharmaceuticals
EMPLOYEES	207

Collegium Pharmaceutical Inc Frequently Asked Questions

What is the ticker symbol for Collegium Pharmaceutical Inc? What does COLL stand for in stocks?

COLL is the stock ticker symbol of Collegium Pharmaceutical Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Collegium Pharmaceutical Inc (COLL)?

As of Fri May 17 2024, market cap of Collegium Pharmaceutical Inc is 1.06 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers.

What is the fair value of COLL stock?

You can check COLL's fair value in chart for subscribers. The fair value of Collegium Pharmaceutical Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Collegium Pharmaceutical Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for COLL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Collegium Pharmaceutical Inc a good stock to buy?

The fair value guage provides a quick view whether COLL is over valued or under valued. Whether Collegium Pharmaceutical Inc is cheap or expensive depends on the assumptions which impact Collegium Pharmaceutical Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for COLL.

What is Collegium Pharmaceutical Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, COLL's PE ratio (Price to Earnings) is 11.39 and Price to Sales (PS) ratio is 1.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. COLL PE ratio will change depending on the future growth rate expectations of investors.